Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers (NCT07041450)
A Cohort Study on Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers
🩺 Plain-English Summary (8th-Grade Level)
This study evaluates a diagnostic screening solution for Alzheimer's disease (AD) using digital cognitive assessments and blood-based biomarkers. The aim is to reduce time-to-treatment for patients who may benefit from disease-modifying therapy (DMT). The study involves 500 patients referred to the MoCA Clinic in Montreal. Clinical stages will be assessed using digital tools from MoCA Test Inc. (MoCA Cognition), and biological stages via blood biomarkers. Data collected includes demographics, cognitive scores, health questionnaires, biomarker levels, and neurologist-determined eligibility for DMT. The study will result in an algorithm to support diagnostic triage and estimate the efficiency and equity of a fast-track diagnostic pathway. Exploratory endpoints include validation of self-administered digital tools, health-economic estimates, and predictors of cognitive decline.
Who can join: Review the eligibility criteria below.
Location: MoCA Clinic and Institute — Greenfield Park, Quebec
Age range: 55 Years to 90 Years
🧪 Interventions in This Study
- Digital MoCA (DIAGNOSTIC_TEST)
- XpressO (DIAGNOSTIC_TEST)
- MoCA (DIAGNOSTIC_TEST)
- Blood-based Biomarkers (BBM) (DIAGNOSTIC_TEST)
- Amyloid Treatment Screening Tool (ATST) (OTHER)
- MoCA Brain Health Questionnaire (MBHQ) (OTHER)
- MoCA Medical Questionnaire (OTHER)
- Functional Activities Questionnaire+ (FAQ+) (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- MoCA Clinic and Institute — Greenfield Park, Quebec
📞 Contact the Study Coordinator
Phone: (514) 758-5033
Email: johanna.gruber@mocacognition.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mild Cognitive Impairment
- Enhancing Frontal Lobes Plasticity in Mild Cognitive Impairment — Toronto, Ontario
- Remote Game-based Exercise Program for Cognitive and Motor Function Improvement — Los Angeles, California
- Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) — Boston, Massachusetts
- Glutathione in Mild Cognitive Impairment — Houston, Texas
- Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy — Morgantown, West Virginia
- Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease — Los Angeles, California
Explore by condition: All Mild Cognitive Impairment clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.